CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I/II Study of Veltuzumab Combined With 90Y-Epratuzumab Tetraxetan in Patients With Relapsed/Refractory, Aggressive Non- Hodgkin's Lymphoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01101581
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:32.043000+00:00
- Published At
- 2021-08-18T00:00:00+00:00
- Record Updated At
- 2021-08-18
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Non Hodgkin\u0027s Lymphoma", "NHL", "Aggressive NHL", "Diffuse Large B-cell Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-08-18"- protocolSection.identificationModule.nctId
"NCT01101581"- protocolSection.identificationModule.officialTitle
"Phase I/II Study of Veltuzumab Combined With 90Y-Epratuzumab Tetraxetan in Patients With Relapsed/Refractory, Aggressive Non- Hodgkin\u0027s Lymphoma"- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.